Cysteinyl leukotriene receptor 1 (cysLT1R) regulates osteoclast differentiation and bone resorption

References

• Xiong J, O'Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012;27:499–505.
   PubMed Web of Science ®Google Scholar
• Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2:389–406.
   PubMed Web of Science ®Google Scholar
• Walsh MC, Kim N, Kadono Y, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33–63.
   PubMed Web of Science ®Google Scholar
• Kim WS, Kim H, Jeong EM, et al. Transglutaminase 2 regulates osteoclast differentiation via a Blimp1-dependent pathway. Sci Rep. 2017;7:10626.
   PubMed Web of Science ®Google Scholar
• Gingery A, Bradley E, Shaw A, et al. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem. 2003;89:165–179.
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292–304.
   PubMed Web of Science ®Google Scholar
• Kim YG, Kang JH, Kim HJ, et al. Bortezomib inhibits osteoclastogenesis and porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption. J Dent Res. 2015;94:1243–1250.
   PubMed Web of Science ®Google Scholar
• Ihn HJ, Kim JA, Cho HS, et al. Diphlorethohydroxycarmalol from Ishige Okamurae suppresses osteoclast differentiation by downregulating the NF-κB signaling pathway. IJMS. 2017;18:2635.
   Google Scholar
• Austen KF. The cysteinyl leukotrienes: where do they come from? What are they? Where are they going? Nat Immunol. 2008;9:113–115.
   PubMed Web of Science ®Google Scholar
• Liu M, Yokomizo T. The role of leukotrienes in allergic diseases. Allergol Int. 2015;64:17–26.
   PubMed Web of Science ®Google Scholar
• Kim DC, Hsu FI, Barrett NA, et al. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J Immunol. 2006;176:4440–4448.
   PubMed Web of Science ®Google Scholar
• Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127:1312–1326.
   PubMed Web of Science ®Google Scholar
• Currie GP, Srivastava P, Dempsey OJ, et al. Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. Q J Med. 2005;98:171–182.
   Google Scholar
• Henderson WR, Jr, Chiang GK, Tien YT, et al. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med. 2006;173:718–728.
   PubMed Web of Science ®Google Scholar
• Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med. 2007;357:1841–1854.
   PubMed Web of Science ®Google Scholar
• Zhao R, Shi WZ, Zhang YM, et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. J Pharm Pharmacol. 2011;63:550–557.
   PubMed Web of Science ®Google Scholar
• Chang E-J, Ha J, Oerlemans F, et al. Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption. Nat Med. 2008;14:966–972.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 2006;39:443–452.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Nakashima T, Taniguchi M, et al. Osteoprotection by semaphorin 3A. Nature 2012;485:69–76.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Nakashima T, Kodama T, et al. Ly49Q, an ITIM-bearing NK receptor, positively regulates osteoclast diferentiation. Biochem Biophys Res Commun. 2010;393:432–438.
   PubMed Web of Science ®Google Scholar
• Chen Q, Hou T, Luo F, et al. Involvement of toll-like receptor 2 and pro-apoptotic signaling pathways in bone remodeling in osteomyelitis. Cell Physiol Biochem. 2014;34:1890–1900.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337–3342.
   PubMed Web of Science ®Google Scholar
• Park JH, Lee NK, Lee SY. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells. 2017;40:706–713.
   PubMed Web of Science ®Google Scholar
• Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun. 2003;305:211–214.
   PubMed Web of Science ®Google Scholar
• Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol. 2014;5:511.
   PubMed Web of Science ®Google Scholar
• Kadono Y, Okada F, Perchonock C, et al. Strength of TRAF6 signalling determines osteoclastogenesis. EMBO Rep. 2005;6:171–176.
   PubMed Web of Science ®Google Scholar
• Boehmler AM, Drost A, Jaggy L, et al. The CysLT1 ligand leukotriene D4 supports alpha4beta1- and alpha5beta1-mediated adhesion and proliferation of CD34+ hematopoietic progenitor cells. J Immunol. 2009;182:6789–6798.
   PubMed Web of Science ®Google Scholar
• Kim MS1, Yang YM, Son A, et al. RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem. 2010;285:6913–6921.
   PubMed Web of Science ®Google Scholar
• Rezaei-Sadabady R, Eidi A, Zarghami N, et al. Intracellular ROS protection efficiency and free radical-scavenging activity of quercetin and quercetin-encapsulated liposomes. Artif Cells Nanomed Biotechnol. 2016;44:128–134.
   PubMed Web of Science ®Google Scholar
• Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005;106:852–859.
   PubMed Web of Science ®Google Scholar
• Guo X, Wei S, Lu M, et al. RNA-Seq investigation and in vivo study the effect of strontium ranelate on ovariectomized rat via the involvement of ROCK1. Artif Cells Nanomed Biotechnol. 2018;30:1–13.
   Google Scholar
• Tsai MK, Lin YC, Huang MY, et al. The effects of asthma medications on reactive oxygen species production in human monocytes. J Asthma 2017;11:1–9.
   Google Scholar